Stock CTLT CATALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Catalent, Inc.

Equities

CTLT

US1488061029

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-06 pm EDT 		5-day change 1st Jan Change
56.37 USD -0.23% Intraday chart for Catalent, Inc. +0.12% +25.46%
May. 03 Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition MT
May. 03 Catalent, Novo Nordisk Antitrust Review Extended by FTC MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
MT
Catalent, Novo Nordisk Antitrust Review Extended by FTC
MT
FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal
DJ
US FTC seeks more information on Novo Nordisk parent-Catalent deal
RE
FTC seeks more information on Novo Holdings-Catalent deal
RE
Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast
RE
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
RE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ANSS, CTLT
PR
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
BU
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48
MT
Sector Update: Health Care Stocks Decline Late Afternoon
MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition
MT
Novo Nordisk parent refiles US application on Catalent deal
RE
Novo Nordisk owner refiles U.S. application for approval of Catalent deal
RE
Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
CI
Cellipont Bioservices Appoints Edwin Beale as Chief Commercial Officer
AQ
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, EVBG, ZFOX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
PR
Novo Nordisk hopes to launch experimental obesity drug this decade
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTLT Stock
  4. News Catalent, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW